Literature DB >> 30415608

Systematic fast-track transition from oncological treatment to dyadic specialized palliative home care: DOMUS - a randomized clinical trial.

Mie Nordly1,2, Kirstine Skov Benthien1,2, Eva S Vadstrup1, Geana P Kurita1,3, Annika B von Heymann-Horan4, Hans von der Maase1,2, Christoffer Johansen1,2,4, Helle Timm5, Jakob Kjellberg6, Per Sjøgren1,2.   

Abstract

Keywords:  Cancer; home care services; palliative care; psychological intervention; quality of life; randomized controlled trial

Mesh：

Year:  2018        PMID： 30415608     DOI： 10.1177/0269216318811269

Source DB:  PubMed          Journal:  Palliat Med        ISSN： 0269-2163            Impact factor:   4.762


× No keyword cloud information.
  4 in total

Review 1.  Use of Theoretical Frameworks in the Development and Testing of Palliative Care Interventions.

Authors:  Mary Pilar Ingle; Devon Check; Daniel Hogan Slack; Sarah H Cross; Natalie C Ernecoff; Daniel D Matlock; Dio Kavalieratos
Journal:  J Pain Symptom Manage       Date:  2021-10-29       Impact factor: 3.612

2.  Comparing two models of outpatient specialised palliative care.

Authors:  Elizabeth Rosted; Birgit Aabom; Bibi Hølge-Hazelton; Mette Raunkiær
Journal:  BMC Palliat Care       Date:  2021-02-18       Impact factor: 3.234

3.  The effectiveness and cost-effectiveness of hospital-based specialist palliative care for adults with advanced illness and their caregivers.

Authors:  Sabrina Bajwah; Adejoke O Oluyase; Deokhee Yi; Wei Gao; Catherine J Evans; Gunn Grande; Chris Todd; Massimo Costantini; Fliss E Murtagh; Irene J Higginson
Journal:  Cochrane Database Syst Rev       Date:  2020-09-30

4.  Cost-effectiveness analysis of systematic fast-track transition from oncological treatment to specialised palliative care at home for patients and their caregivers: the DOMUS trial.

Authors:  Christine Marie Bækø Halling; Rasmus Trap Wolf; Per Sjøgren; Hans Von Der Maase; Helle Timm; Christoffer Johansen; Jakob Kjellberg
Journal:  BMC Palliat Care       Date:  2020-09-15       Impact factor: 3.234
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.